U.S. markets closed
  • S&P Futures

    3,302.00
    +2.75 (+0.08%)
     
  • Dow Futures

    27,241.00
    +98.00 (+0.36%)
     
  • Nasdaq Futures

    11,118.75
    -30.75 (-0.28%)
     
  • Russell 2000 Futures

    1,490.10
    +1.30 (+0.09%)
     
  • Crude Oil

    39.55
    -0.05 (-0.13%)
     
  • Gold

    1,909.00
    +1.40 (+0.07%)
     
  • Silver

    24.58
    +0.06 (+0.25%)
     
  • EUR/USD

    1.1710
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    0.6640
    -0.0070 (-1.04%)
     
  • Vix

    26.86
    -0.92 (-3.31%)
     
  • GBP/USD

    1.2745
    +0.0008 (+0.06%)
     
  • USD/JPY

    105.0350
    +0.1110 (+0.11%)
     
  • BTC-USD

    10,542.13
    +0.37 (+0.00%)
     
  • CMC Crypto 200

    215.06
    +1.31 (+0.61%)
     
  • FTSE 100

    5,829.46
    +25.17 (+0.43%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

Arbutus to Present at Upcoming May 2019 Conferences

WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and CEO, will present at the following conferences in May 2019:

UBS Global Healthcare Conference
– New York

Monday, May 20, 2019, 1:00 PM ET

 

 

RBC Capital Markets Healthcare Conference
– New York

Tuesday, May 21, 2019, 11:00 AM ET

Live webcasts of the presentations can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.  A replay of the webcasts will be available for 90 days following the live presentations.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information


Investors

Mark Murray
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com